Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Pharmacology Research & Perspectives|May 2, 2025
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia VeraAlbert Qin, Kazuya Shimoda, Shanshan Suo, et al.
Leukemia & Lymphoma|July 17, 2026
Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia veraAnthony Michael Hunter, Albert Qin, Lucia Masarova, et al.
EMBO Reports|January 19, 2008
Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activationNoritaka Yasuda, Shin-ichiro Miura, Hiroshi Akazawa, et al.
European Heart Journal. Digital Health|January 30, 2023
Accuracy of wristwatch-type photoplethysmography in detecting atrial fibrillation in daily lifeNoriko Matsushita Nonoguchi, Kyoko Soejima, Ayumi Goda, et al.
Circulation. Arrhythmia and Electrophysiology|April 29, 2020
Remote Management of Pacemaker Patients With Biennial In-Clinic Evaluation: Continuous Home Monitoring in the Japanese At-Home Study: A Randomized Clinical TrialEiichi Watanabe, Fumio Yamazaki, Toshihiko Goto, et al.
Experimental Hematology & Oncology|June 21, 2023
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia veraJie Jin, Lei Zhang, Albert Qin, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|December 15, 2010
Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study)Takeshi Yamashita, Hiroshi Inoue, Ken Okumura, et al.
Cardiovascular Research|June 29, 2012
Disease characterization using LQTS-specific induced pluripotent stem cellsToru Egashira, Shinsuke Yuasa, Tomoyuki Suzuki, et al.
Journal of Hematology|April 22, 2024
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b TreatmentShan Shan Suo, Rong Feng Fu, Albert Qin, et al.
The Lancet. Haematology|November 5, 2025
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 studyRuben Mesa, Harinder Gill, Lei Zhang, et al.
Pageof 12